The first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial support the hypothesis that higher brain amyloid levels represent an early preclinical stage of Alzheimer’s disease (AD). An analysis of screening data from the trial showed that elevated amyloid in clinically normal older adults was associated with lower cognitive test scores and increased self-reports of subtle changes in cognitive function.
